Dr. Paul Alan Gonzales M.D.

Recommended Articles

• Living with Lymphoma Day by Day

  A majority of individuals diagnosed with lymphoma find that they have to make a great deal of adjustments to their lives. There are several physical, emotional, social, and everyday obstacles from diagnosis to remission.Living with lymphoma can be different for every individual, which is why it is...

• Treatment Update for Hodgkin Lymphoma

  Over time, research has uncovered ways of treating Hodgkin lymphoma (HL) to produce an 80% to 90% cure rate. For the remaining 10% to 20% who are either resistant to the primary treatment or have relapsed, their cancer can still be fatal.The standard care for those not yet cured has been a two-step...

• 7-year-old with Lymphoma Joins and Inspires Lacrosse Team

  Sports have a way of bringing together families, strangers, and communities. All over the world people celebrate games and competitions and use them to lift people’s spirits and strengthen bonds. Sporting events are also frequently used to raise awareness about important causes, whether locally or...

• Teen with Hodgkin Lymphoma Skates with Her Hero, Mario Lemieux

  Lillian Tarasiewicz was diagnosed with stage 3B Hodgkin lymphoma in October of 2015. She currently resides in South Carolina, but because of her father’s Pennsylvania background, she grew up with a love for hockey and for the Pittsburgh Penguins. She always felt a special connection to Mario...

• Potential Causes of Leukopenia

  IntroductionA decrease in the number of white blood cells (WBCs) is referred to as leukopenia. There are several causes for leukopenia. It may be due to certain drugs, cancer, radiation and chemotherapy for cancer, stem cell transplant, surgery, steroids, or autoimmune disorders. The immune system...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...